BRAF and non-small cell lung carcinoma: With the widespread application of next-generation sequencing (NGS), more fusions and co-mutations have been discovered, that play a critical role in accurate prescription of targeted drugs and predicting the therapeutic efficacy.[1] Anaplastic lymphoma kinase (ALK) rearrangements and BRAF V600E mutations are rare genetic variants in NSCLC with incidences of about 5% and 2% respectively.[2,3] Complex EML4-ALK fusion together with BRAF V600E co-mutation is more uncommon, and the standard of care is unclear.